Introduction
Cerebral amyloid angiopathy (CAA), also known as congophilic angiopathy or cerebrovascular amyloidosis, is characterized by amyloid deposition in the walls of small vessels in the cerebral cortex and leptomeninges in the ageing brain. 1 -3 CAA is regarded as an important factor for primary nontraumatic spontaneous cortical and subcortical intracranial haemorrhage in W Wei, W Zhang, Y Huang et al.
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normotensive elderly patients. 2, 3 Hypoperfusion caused by vessel wall deposition of β-amyloid (Aβ) may also manifest as leucoencephalopathy, brain atrophy or ischaemia. 4 The Aβ protein is derived from the amyloid precursor protein (APP) through a series of enzymatic cleavages. 5 Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that have been shown to play an important role in the regulation of many cell behaviours including cell proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis and host defence. 6 MMPs can influence cell-matrix interactions in the human brain and may also be involved in disintegration of the basement membranes of microvessels during cerebral ischaemia. 7, 8 The members of the MMP family with gelatinase activity, MMP-2 and MMP-9, have been shown to play a central role in the catabolism of Aβ peptides. 9 Synthesized DL-3-n-butylphthalide (DL-NBP) was approved for clinical use in stroke patients by the State Food and Drug Administration of China in 2002. 10 DL-NBP is a synthesized chiral compound that contains both L-and D-isomers. Previous studies in rats have shown that NBP has neuroprotective effects that are beneficial for stroke treatment, including improving microcirculation dysfunction during ischaemia, 11 decreasing the area of cerebral infarct in focal cerebral ischaemic rats, 12, 13 and improving energy metabolism in mice with complete brain ischaemia. 14 To date, the detailed molecular mechanisms associated with the therapeutic effects of DL-NBP remain unclear.
The present study investigated the therapeutic effects of DL-NBP in rats with chronic cerebral hypoperfusion. The relevant molecular mechanisms are discussed, with particular focus on the influence of DL-NBP on regulation of the APP Aβ40, MMP-2 and MMP-9 proteins.
Materials and methods

ANIMALS AND EXPERIMENTAL DESIGN
A total of 144 male specific-pathogen-free (SPF) Wistar rats (aged 3 -4 months) weighing 250 -300 g were obtained from the China Academy of Military Medical Science, Beijing, China. The rats were group housed (five rats per cage) and maintained in a temperature-controlled room (mean ± SD 23 ± 1°C) at 55% humidity in 12-h light/dark cycles with free access to water and food. All experimental procedures were carried out in accordance with the institutional guidelines of the Experimental Animal Centre, China Academy of Military Medical Science. The study was approved by the Medical Ethics Committee of the Third Military Medical University, Chongqing, China.
Before surgery, the rats were randomly divided into three groups using computergenerated random numbers: the control group (sham-operation); the ischaemic group; and the ischaemic plus drug treatment group. Under sodium pentobarbital (40 mg/kg, intraperitoneally) anaesthesia, a ventral midline incision was made and the bilateral common carotid arteries were exposed and gently separated from the carotid sheath and vagus nerve. During the surgical procedure, the body temperature of the rats was kept stable at 37°C using a heating pad. In the rats assigned to the ischaemic groups, each artery was double ligated with a 5-0 silk suture. The rats in the control groups received the same operation without ligation. Each group consisted of 48 rats with similar body weights (mean ± SD 234 ± 14 g). At 10 days after the surgical procedure, DL-W Wei, W Zhang, Y Huang et al.
DL-3-n-Butylphthalide in chronic cerebral hypoperfusion NBP 2 mg/kg (Shijiazhuang Pharma Group NBP Pharmaceutical Co. Ltd, Shijiazhuang, China) or the equivalent volume of saline (vehicle) was given orally once daily for 60 days. All analyses were carried out postinitiation of drug treatment as indicated.
MORRIS WATER MAZE TASK
At 33 days after surgery, the Morris water maze task 15 was carried out for 20 rats from each group. The apparatus consisted of a circular water tank 120 cm in diameter and 50 cm in height. To make the water opaque, 1 kg of powdered milk was added; the water temperature was maintained at a mean ± SD of 23 ± 1°C. A translucent acrylic platform (10 cm in diameter) was located in the centre of the northeast or southwest quadrant during training. The top of the platform was approximately 1.5 cm below the surface of water. During the training period of the task, rats underwent one trial per day for 5 days consecutively from days 33 to 37 after surgery. The starting position (east, west, south, or north) for each trial was pseudorandomly chosen and counterbalanced across all experimental groups as described previously. 13 Half of the rats were trained using the northeast platform position and the other half were trained for the southwest position. The experimenter conducting the Morris water maze was blinded to the treatment groups.
The rats were gently placed into the water facing the side walls of the maze from one of the four preplanned starting positions (east, west, south, or north). The swimming paths of the rats were monitored by a video camera linked to a computer through an image analyser. For each training trial, the latency to escape onto the hidden platform and the path length were recorded. The rats were given a maximum of 60 s to find the hidden platform. If the rat failed to find the platform within 60 s, the training was terminated and a maximum score of 60 s was assigned. The rat was then guided to the hidden platform by hand and allowed to stay on the platform for 10 s before being removed from the water.
A probe test, in which the hidden platform was removed, was conducted immediately after the last trial on training day 5. The rats were released into the water from the opposite quadrant with respect to the training quadrant. The rats were allowed to swim for 60 s in the pool before they were removed from the water by hand.
WESTERN BLOT ANALYSIS
For Western blot analysis, four rats per group were sacrificed for each treatment group at each time point (0, 7, 14, 30 and 60 days) using an overdose of carbon dioxide. For each rat at each time point, proteins were extracted from cerebral cortex and cerebral hippocampal tissue (100 -200 mg) using radioimmunoprecipitation lysis buffer (50 mM Tris, 150 mM saline, 0.1% sodium dodecyl sulphate [SDS], 0.5% sodium deoxycholate, 1% Triton X100). Total protein concentrations were estimated with a bicinchoninic acid (BCA) protein assay kit (Vigorous Biotechnology Beijing Co. Ltd, Beijing, China). Samples containing 150 µg protein were separated by 10% SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked with 1× phosphate-buffered saline, pH 7.4, containing 3% bovine serum albumin for 2 h at 4 °C. The membranes were then incubated with primary mouse monoclonal antibodies to Aβ40, MMP-2 and MMP-9 (1 : 1000 dilution; Calbiochem ® , Merck4Biosciences, Paris, France) overnight at 4°C. The membrane was washed three times with 50 mM Tris, 150 mM saline, pH 7.5 (TBS) containing 5% (w/v) non-fat dry milk, and 
Ltd, Tokyo, Japan). The protein levels were normalized to β-actin.
IMMUNOHISTOCHEMICAL STAINING
For immunohistochemical analysis, four rats per group were sacrificed for each treatment group at days 3 and 14 using an overdose of carbon dioxide. Tissue sections (5 µm) were prepared from formalin-fixed, paraffinembedded specimens of the rat cerebral cortex, then deparaffinized in fresh xylene and rehydrated in descending concentrations of alcohol (100 -70%). Serial dilutions and different antigen retrieval methods were performed for each antibody to optimize staining quality. After blocking with 3% nonfat milk, the sections were incubated with primary antibodies to Aβ40, MMP-2 and MMP-9 (1 : 1000 dilution; Calbiochem ® , Merck4Biosciences) for 30 min at room temperature. Sections were then washed twice using TBST and incubated with a biotinylated horseradish peroxidase goat antimouse secondary antibody (1 : 500 dilution; Calbiochem ® , Merck4Biosciences) for 30 min. Sections were incubated with streptavidin-biotin complex (SABC) for 50 min at room temperature and colour was developed with diaminobenzidine (DAB) for 40 min at room temperature using SABCperoxidase and DAB (AR1022) kits (Wuhan Boster Biological Technology, Wuhan, Hubei, China) according to the manufacturer's instructions.
The slides were then counterstained with Mayer's haematoxylin for 1 min. The immunohistochemical staining was examined and photographed at × 400 magnification using an Olympus CX42 light microscope (Olympus Optical Co., Tokyo, Japan).
STATISTICAL ANALYSES
Statistical analyses were performed using SPSS ® statistical software, version 7.5 (SPSS Inc., Chicago, IL, USA) for Windows ® .
Statistical differences between the three treatment groups were evaluated using the two-tailed Student's t-test. A P-value < 0.05 was considered to be statistically significant.
Results
In the Morris water maze task, the learning ability of rats in the DL-NBP treatment group was significantly improved compared with rats in the ischaemic group. The escape latency time of the ischaemic group was significantly increased compared with the sham group (P < 0.01; Table 1 ), whereas that of the ischaemic plus DL-NBP-treated group was significantly decreased compared with the ischaemic group (P < 0.01; Table 1 ). Compared with baseline (day 0), levels of Aβ40 and MMP-2 protein in the cerebral cortex of rats were significantly increased at day 60 in the ischaemic group (P < 0.01; Fig.  1A ), whereas there was no significant difference in MMP-9 protein levels compared with baseline. The levels of these proteins were not markedly increased in the hippocampus compared with baseline (Fig. 1B) . Sham-operated group 37.3 ± 1.5 30.1 ± 1. 
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At day 60, MMP-2 and Aβ40 protein levels in the cerebral cortex of hypoperfused rats were significantly decreased in rats in the ischaemic plus DL-NBP-treated group compared with the ischaemic group (P < 0.05 and P < 0.01, respectively; Fig. 2A ). There was no alteration in MMP-9 protein level in the cerebral cortex of rats treated with DL-NBP. Protein levels of Aβ40, MMP-2 and MMP-9 in the hippocampus were not significantly different between the three groups (Fig. 2B) .
Immunohistochemical analysis of the cerebral cortex of hypoperfused rats demonstrated that Aβ40 and MMP-2 were deposited in venous endothelial cells at day 3 after surgery and in arterial endothelial cells at day 14 (Fig. 3) . No deposition of MMP-9 was observed (data not shown).
FIGURE 2:
Protein levels of the amyloid precursor protein β-amyloid 40 (Aβ40), matrix metalloproteinase-2 (MMP-2) and MMP-9 assessed by Western blot analysis at days 0 and 60 after surgery to induce chronic cerebral hypoperfusion (ischaemic group), or after chronic cerebral hypoperfusion plus treatment with DL-3-n-butylphthalide (ischaemic plus DL-NBP) in (A) the cerebral cortex and (B) the hippocampus of rats (mean ± SD; # P < 0.05, ## P < 0.01 compared with baseline [day 0]; *P < 0.05, **P < 0.01 compared with ischaemic group; two-tailed Student's t-test) 
Discussion
The most common type of CAA is caused by Aβ and is, therefore, termed the Aβ type. Deposition of Aβ protein in the small cerebral vessels can efficiently penetrate the arterioles of the cortex. 16 The present study demonstrated an accumulation of Aβ40 in the endothelial cells of cerebral veins and arteries in rats with chronic cerebral hypoperfusion. Forms of Aβ protein can stimulate the expression of many genes, including those that encode proteins such as urokinase-type plasminogen activator (uPA) and uPA receptor, MMP-2 and MMP-9. 17, 18 The Aβ protein is derived from APP through a series of enzymatic cleavages, 5 which is why we investigated the changes in the APP Aβ40, MMP-2 and MMP-9 protein levels. The present study showed that the accumulation of Aβ40 leads to an increase in MMP-2, but not MMP-9, deposition. The results were consistent with findings from a previous study that demonstrated that chronic cerebral hypoperfusion upregulated MMP-2 but not MMP-9 in the vascular endothelium of white matter in rats. 19 A previous study indicated that DL-NBP plays an important neuroprotective role in cerebral ischaemia, vascular dementia, amyotrophic lateral sclerosis and Alzheimer's disease. 20 At present, DL-NBP is being used in clinical practice in China for the treatment of ischaemic patients. The 21 used an amyotrophic lateral sclerosis mouse model to demonstrate that DL-NBP significantly improved motor performance accompanied by the downregulation of the transcription factor nuclear factor κB p65 and tumour necrosis factor-α. Additionally, a slight upregulation of nuclear factor (erythroid-derived 2)-like 2 and haemoxygenase-1 were also observed. In the present study DL-NBP improved the memory and learning capabilities of hypoperfused rats and reduced levels of Aβ40 and MMP-2 protein in the cerebral cortex.
In conclusion, the present study indicated that DL-NBP has therapeutic effects on chronic cerebral hypoperfusion. It has also provided insight into the potential molecular mechanisms underlying the actions of DL-NBP that will aid understanding of the therapeutic effect of DL-NBP.
